Mizuho keeps Buy rating for Immuneering stock at USD 12.00

Published on 10/05/2026 at 08:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Immuneering lost USD 0.27 per share in the second quarter of 2026, missing USD 0.26 consensus. A USD 17.50 average target from seven analysts covers Immuneering stock.

IMRX, US45254E1073, Illustration mit AI erstellt.

Mizuho Securities maintained a Buy rating and a USD 12.00 price target for Immuneering stock on October 2, 2026, according to Moomoo. The same date brought a new clinical update, as Immuneering announced that atebimetinib data would be presented at the Society for Immunotherapy of Cancer meeting.

Atebimetinib advances toward combination study

BioSpace reported on October 2, 2026, that the company plans to present preclinical findings showing atebimetinib enhanced PD-1 checkpoint blockade in RAS mutant tumor models. The poster is scheduled for November 6, 2026, at the meeting in Phoenix, with the findings supporting a planned Phase 2 study combining atebimetinib with PD-1 blockade in lung cancer patients.

Immuneering's investor-relations page describes atebimetinib as an oral, once-daily Deep Cyclic Inhibitor of MEK and identifies a pivotal Phase 3 pancreatic cancer trial as the lead program. The company also lists additional combination studies in lung cancer, placing the November presentation within a broader clinical development plan.

Loss and analyst expectations diverge

Canli Capital lists the August 5, 2026 filing as Immuneering's fiscal second-quarter report. MarketBeat reported a quarterly loss of USD 0.27 per share against a USD 0.26 consensus loss, a USD 0.01 miss.

MarketBeat also counted four Buy ratings, two Strong Buy ratings and one Sell rating among seven brokerages, producing a USD 17.50 average 12-month target. That target is materially above the USD 12.00 level maintained by Mizuho, showing that the analyst range remains wide even as the consensus leans positive.

Small-cap biotech valuation remains sensitive

As of October 2, 2026, Immuneering had a market capitalization of USD 147.8 million. Its 52-week range ran from USD 3.86 to USD 8.48, giving investors a concrete measure of the valuation gap around a company whose lead assets remain in clinical development.

The central issue is execution: the SITC data are preclinical, while the planned lung cancer study and the Phase 3 pancreatic program still depend on later clinical evidence. The company has identified atebimetinib as its lead candidate, but its development stage leaves clinical milestones more important than near-term commercial revenue.

IMRX market context

IMRX traded at USD 4.07 on Nasdaq on October 2, 2026 at 4:00 p.m. ET, up 0.99 percent from USD 4.03. The October 2 market capitalization was USD 147.8 million, and the 52-week range was USD 3.86 to USD 8.48.